Turku, Finland – 29th June 2023: Drug delivery and development company DelSiTech today reported positive topline results from its Phase 1 clinical trial, evaluating the safety and tolerability of DST-2105, DelSiTech’s first of its kind, silica-based, long-acting demulcent eye drop product. Read more…
Turku, Finland – March 15, 2023 – DelSiTech Ltd, a Finnish drug delivery and drug development company, today announces that it has been awarded a grant from the Bill & Melinda Gates Foundation to develop long-acting injectable formulations ensuring the slow release of human immunodeficiency virus (HIV) vaccine. This funding marks the third grant awarded from the Bill […]
Parsippany, N.J. and Turku, Finland – July 6, 2022 – IVERIC bio, Inc. (Nasdaq: ISEE) and DelSiTech Ltd, announced today an exclusive global license agreement providing Iveric Bio with the right to develop and commercialize new formulations of Zimura® (avacincaptad pegol) using DelSiTech’s silica-based sustained release technology. As part of Iveric Bio’s lifecycle expansion plan for Zimura, the Company […]
Turku, Finland – 18 May 2022: DelSiTech Ltd, the leading silica drug delivery technology company, based in Finland and Anticancer Bioscience Ltd., an innovative China-base and international company pioneers in synthetic lethal approaches to precision oncology, today announced a notable collaboration pertaining to the development of silica-based long-acting controlled release treatments in oncology. The collaboration joins […]
